telitacicept   Click here for help

GtoPdb Ligand ID: 11827

Synonyms: RC18 | Tai'ai®
Approved drug Immunopharmacology Ligand
telitacicept is an approved drug (China (2021))
Compound class: Peptide or derivative
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
No information available.
Summary of Clinical Use Click here for help
Telitacicept's first global approval was issued in China in March 2021 [1]. It is indicated as a treatment for patients with active SLE.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05078710 Telitacicept in Primary APS Patients Phase 2 Interventional Peking Union Medical College Hospital
NCT04905212 A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Phase 2 Interventional RemeGen Co., Ltd.
NCT04625153 RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial Phase 2 Interventional RemeGen Co., Ltd.